Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Fernández-Chico

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Actas Dermo-Sifiliograficas|November 2, 2010
[Pseudofolliculitis barbae]M Ribera, N Fernández-Chico, M Casals
Actas Dermo-Sifiliograficas|March 2, 2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter StudyJ Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, et al.
Actas Dermo-Sifiliograficas|May 22, 2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter StudyJ Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Actas Dermo-Sifiliograficas|November 2, 2010
[Pseudofolliculitis barbae]M Ribera, N Fernández-Chico, M Casals
Actas Dermo-Sifiliograficas|March 2, 2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter StudyJ Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, et al.
Actas Dermo-Sifiliograficas|May 22, 2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter StudyJ Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, et al.
Pageof 1